AI diagnostics
“ATMAN AI”, an Artificial Intelligence algorithm that can detect the presence of COVID-19 disease in Chest X Rays, has been developed to combat COVID fatalities involving lung. ATMAN AI is used for chest X-ray screening as a triaging tool in Covid-19 diagnosis, a method for rapid identification and assessment of lung involvement. This is a joint effort of the DRDO Centre for Artificial Intelligence and Robotics (CAIR), 5C Network & HCG Academics. This will be utilized by online diagnostic startup 5C Network with support of HCG Academics across India.
Triaging COVID suspect patients using X Ray is fast, cost effective and efficient. It can be a very useful tool especially in smaller towns in India owing to lack of easy access to CT scans there.
This will also reduce the existing burden on radiologists and make CT machines which are being used for COVID be used for other diseases and illness owing to overload for CT scans.
The novel feature namely “Believable AI” along with existing ResNet models have improved the accuracy of the software and being a machine learning tool, the accuracy will improve continually.
Chest X-Rays of RT-PCR positive hospitalized patients in various stages of disease involvement were retrospectively analysed using Deep Learning & Convolutional Neural Network models by an indigenously developed deep learning application by CAIR-DRDO for COVID -19 screening using digital chest X-Rays. The algorithm showed an accuracy of 96.73%.
read more at http://indiaai.gov.in/news/drdo-cair-5g-network-and-hcg-academics-develop-atman-ai
Lire l'article complet sur : indiaai.gov.in
Numerous studies demonstrate frequent mutations in the genome of SARS-CoV-2. Our goal was to statistically link mutations to severe disease outcome.
We found that automated machine learning, such as the method of Tsamardinos and coworkers used here, is a versatile and effective tool to find salient features in large and noisy databases, such as the fast growing collection of SARS-CoV-2 genomes.
In this work we used machine learning techniques to select mutation signatures associated with severe SARS-CoV-2 infections. We grouped patients into 2 major categories (“mild” and “severe”) by grouping the 179 outcome designations in the GISAID database.
A protocol combined of logistic regression and feature selection algorithms revealed that mutation signatures of about twenty mutations can be used to separate the two groups. The mutation signature is in good agreement with the variants well known from previous genome sequencing studies, including Spike protein variants V1176F and S477N that co-occur with DG14G mutations and account for a large proportion of fast spreading SARS-CoV-2 variants. UTR mutations were also selected as part of the best mutation signatures. The mutations identified here are also part of previous, statistically derived mutation profiles.
An online prediction platform was set up that can assign a probabilistic measure of infection severity to SARS-CoV-2 sequences, including a qualitative index of the strength of the diagnosis. The data confirm that machine learning methods can be conveniently used to select genomic mutations associated with disease severity, but one has to be cautious that such statistical associations – like common sequence signatures, or marker fingerprints in general – are by no means causal relations, unless confirmed by experiments.
Our plans are to update the predictions server in regular time intervals. While this project was underway more than 100 thousand sequences were deposited in public databases, and importantly, new variants emerged in the UK and in South Africa that are not yet included in the current datasets. Also, in addition to mutations, we plan to include also insertions and deletions which will hopefully further improve the predictive power of the server.
The study was funded by the Hungarian Ministry for Innovation and Technology (MIT) , within the framework of the Bionic thematic programme of the Semmelweis University.
Read the entire study at https://www.biorxiv.org/content/10.1101/2021.04.01.438063v1.full
Access the online portal mentioned above at https://covidoutcome.com/
Lire l'article complet sur : www.biorxiv.org